Tome Biosciences

Cambridge, United States Founded: 2021 • Age: 5 yrs
CRISPR-based gene insertion platform for genomic medicines is developed.

About Tome Biosciences

Tome Biosciences is a Healthcare company based in Cambridge (United States) founded in 2021. CRISPR-based gene insertion platform for genomic medicines is developed. Tome Biosciences has raised $213 million across 2 funding rounds from investors including Fujifilm, ARE and Bruker. Tome Biosciences has completed 1 acquisition, including Replace Therapeutics. Its chief executive, as recorded, is Mike Lucero. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include Senti Biosciences, Poseida Therapeutics and ADARx Pharmaceuticals; 3 of its 3 listed competitors have raised funding.

Company details

Tome Biosciences was founded in 2021 and is headquartered in Cambridge, United States. A gene insertion platform is developed by the company within the biotechnology sector, focusing on genomic medicines. CRISPR technologies are employed to integrate any genetic sequence into any genome. This approach supports the creation of treatments for patients via genomic medicines and advanced cell therapies. Operations center on research and development for therapeutic applications.

  • Headquarters Cambridge, United States
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website tome.bio
  • Social LinkedIn
Key Metrics

Funding Insights of Tome Biosciences

Tome Biosciences has successfully raised a total of $213M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $213M
  • Total Rounds 2
  • First Round $213M

    (Dec 2023)

  • Investors Count 8

All 2 funding rounds of Tome Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2023Series A–a16z, Arch Venture Partners
–
Dec 2023$213MSeries B–a16z, Arch Venture Partners
–
Valuation history

8 investors in total: 8 institutional.

Investors in Tome Biosciences

Tome Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Fujifilm, ARE and Bruker.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
a16z.com
Venture capital firm focused on life science companies
1986archventure.comChicago, United States
Corporate backed venture capital fund investing in multiple sectors
gv.comMountain View, United States
Venture capital is directed toward healthcare companies by Longwood Fund.
longwoodfund.comBoston, United States
US focused venture capital firm
polarispartners.comBoston, United States
Diversified research instrument systems are manufactured and supplied.
1960bruker.comUnited States
Multiple sectors are invested in by the venture capital firm.
1934fujifilm.comMinato, Japan
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
1994are.comPasadena, United States
Premium access

Investor details for Tome Biosciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Tome Biosciences

47 people are tracked at Tome Biosciences (12 in leadership, 35 in team).

NameRoleGroup
Mike Lucero
CEOLeadership
Xiarong Shi
DirectorLeadership
Adrianne Monsef
Senior Director, Program Team LeadLeadership
Diane W.
Chief People OfficerLeadership
Jun Jiang
Senior DirectorLeadership
Jesse Cochrane
Associate DirectorLeadership
Ravindra Amunugama
Associate Director- Cell TherapyLeadership
Gabriela Cline
Director, HRBPLeadership
Chong Luo
Director, Cell TherapyLeadership
Markvic Naniong
Associate DirectorLeadership
Jie Wang
Associate DirectorLeadership
J Michael Sutton
Senior Scientist, Head Of Mass Spec GroupLeadership
Qiang Wang
Senior ScientistTeam
Medina Geyer
Senior Research AssociateTeam
Patrick Tavares
Senior Scientist, Cell TherapyTeam
Saloni Matta
Senior Research AssociateTeam
Sara Ashrafi
ScientistTeam
Patrick Hanna
Scientist IITeam
Angela Nan
Scientist ITeam
Anya Wilczynski
Human Resources ManagerTeam

27 more people are available in the full profile.

Premium access

Complete people profiles for Tome Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Tome Biosciences

Tome Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Replace Therapeutics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
CRISPR-based genome editing platform is developed for genetic diseases.
0Jan 2024β€’β€’β€’β€’
Premium access

Complete acquisition details for Tome Biosciences

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Tome Biosciences

3 dated milestones of Tome Biosciences across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Tome Biosciences is founded.
  2. Funding First funding round of $213.0M.
  3. Acquisition Acquires Replace Therapeutics.

Competitors of Tome Biosciences

Tome Biosciences has 3 listed competitors in our database, 3 of them funded. They include Senti Biosciences, Poseida Therapeutics and ADARx Pharmaceuticals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
sentibio.com2016San Francisco, United States$158M
Cell-based therapies for cancer treatment are developed.
poseida.com2015San Diego, United States$323.78M259
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
adarx.com2019San Diego, United States$352.5M44
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
Premium access

Detailed competitors of Tome Biosciences

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Tome Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Tome Biosciences

Premium access

Complete news archive for Tome Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tome Biosciences

Tome Biosciences was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Tome Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Mike Lucero is the CEO of Tome Biosciences, as recorded in our data.

Tome Biosciences is a funded company, having raised a total of $213M across 2 funding rounds to date.

Tome Biosciences was founded in 2021 and is headquartered in Cambridge, United States. A gene insertion platform is developed by the company within the biotechnology sector, focusing on genomic medicines. CRISPR technologies are employed to integrate any genetic sequence into any genome. This approach supports the creation of treatments for patients via genomic medicines and advanced cell therapies. Operations center on research and development for therapeutic applications.

Tome Biosciences's top competitors include Senti Biosciences, Poseida Therapeutics and ADARx Pharmaceuticals.

Tome Biosciences has made 1 acquisition, including Replace Therapeutics.

Tome Biosciences has 8 investors. Key investors include Fujifilm, ARE, Bruker, Arch Venture Partners, and Andreessen Horowitz.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available